Mission
FRAXA Research Foundation is dedicated to accelerating Fragile X research for effective treatments. They fund research grants and fellowships at top universities worldwide and partner with pharmaceutical companies to bridge the gap between discoveries and treatments. FRAXA’s efforts are likely to benefit people affected by autism, Alzheimer’s, and other brain disorders.
Basic Information
Tax-Exempt
Address
10 PRINCE PL STE 203, Newburyport, MA, United States 01950-2657
View all Newburyport charitiesFounded in
1994
EIN
04-3222167
Total Assets
$3.532 million
UN Sustainable Development Goals Supported
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.
Showing 1 of 1 goals
At a Glance
World Fragile X Day
Celebrate World Fragile X Day to honor Fragile X research and support families affected by the syndrome. Landmarks worldwide light up in recognition of Fragile X Awareness.
BK Channel Openers
Discover the promising new BK channel opener, SPG601, poised to enter clinical trials. It aims to restore synaptic function and address core symptoms of Fragile X Syndrome.
Clinical Trials of Zatolmilast
Tetra Therapeutics’ large scale clinical trials of Zatolmilast aim to treat males with Fragile X. This significant trial is based on FRAXA’s foundational research.
Impact Stats
$34.8M
Direct Investment
Direct Investment in Fragile X Research
FRAXA has invested $34.8 million directly into Fragile X research, supporting groundbreaking work aimed at finding effective treatments and a cure.
641
Research Grants
Research Grants Awarded
FRAXA has awarded 641 research grants to teams actively investigating Fragile X Syndrome, highlighting their commitment to fostering innovative research.
33
Programs in Development
Industry-Wide Pipeline
FRAXA’s initiatives have led to an industry-wide pipeline of programs in development across many companies, crucial to the mass effort to find new options for people affected by Fragile X.
Past Events
World Fragile X Day 2024
07/22/2024
Celebrate World Fragile X Day on July 22, 2024 by lighting up landmarks. Join us in honoring Fragile X research and supporting affected families worldwide.
Tetra Therapeutics Phase 3 Trial
05/20/2024
Tetra Therapeutics has launched large-scale clinical trials of their phosphodiesterase (PDE) inhibitor for males aged 9-45 with Fragile X syndrome, based on FRAXA’s foundational research.
Impact Reports
MIP Score (Beta)
The MIP Score is in beta! We'd love any feedback you may have.
The MIP Score and it's methodology is purely used as a way to visualize how a nonprofits public financial data compares against others. It doesn't reflect the unique circumstances and impact that a nonprofit has.The MIP Score should never be used to say one charity is better than another.
Overall Score
66
64
/100
Program Expense Ratio
93.40%
20
/20
Program Revenue Growth
0.00%
2
/20
Leverage Ratio
0.002644
20
/20
Working Capital Ratio
1.856
14
/20
Fundraising Efficiency
3.104
8
/20
Latest Filing Data: Form 990
Fiscal Year:2022
Source:Source: Self-reported by organization
Financial Details
Revenue
| Category | Amount | Percentage |
|---|---|---|
| Contributions, Gifts, and Grants | 1.695M | 84.01% |
| Program Services | 0 | 0.00% |
| Investment Income | 42.01K | 2.08% |
| Sales of Non-Inventory Assets | 229.8K | 11.39% |
| Other Notable Sources | 0 | 0.00% |
| Total Revenue | 2.018M | 100.00% |
Related Nonprofits
Kidney Cancer Association
Med Research
General Medical ResearchFraunhofer USA Inc.
Med Research
General Medical ResearchJohn Paul II Medical Research Institute
Med Research
General Medical ResearchSouthwest Autism Research & Resource Center
Med Research
General Medical ResearchIsar Incorporated
Med Research
General Medical Research